Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 6/1/1998


1.		Phase III Randomized, Double-Blind Study of Daily x 14 Subcutaneous IL-11 vs Placebo for Severe Chemotherapy-Induced Thrombocytopenia (Summary Last Modified 06/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				16 and over				Pharmaceutical / Industry				GENE-C9504-14 NCI-V96-0810

Last Modified: 11/1/1998 First Published: 9/1/1998


2.		Phase III Randomized Study of Interleukin-11 for Chemotherapy-Induced Thrombocytopenia in Patients With Solid Tumors or Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				18 and over				Pharmaceutical / Industry				MRMC-CTCA-9705 GENE-C9707-14, NCI-V98-1440

Last Modified: 6/21/2007 First Published: 6/1/1998


3.		Phase II Study of Recombinant Human Interleukin-11 with Sargramostim (GM-CSF) for Acute Myeloid Leukemia Patients Receiving High-Dose Cytarabine During Induction and Consolidation Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Completed				18-55				NCI				E-3997 E3997

Last Modified: 4/1/2002 First Published: 12/1/1999


4.		Phase II Study of Interleukin-11 With Filgrastim (G-CSF) in the Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors (Summary Last Modified 04/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				70 and under				NCI				FHCRC-1365.00 NCI-G99-1622, NCT00004157


5.		Interleukin 11, Thrombocytopenia, CML, Imatinib in CML Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Closed				Not specified				Other				2004-0113 NCT00493181

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute